Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 64, Issue 5, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02233-19
Keywords
phenotypic screening; drug discovery; Balamuthia mandrillaris; granulomatous amoebic encephalitis; Balamuthia amoebic encephalitis; antiparasitic agents; Balamuthia; MMV Malaria Box; MMV Pathogen Box
Categories
Funding
- Georgia Research Alliance
Ask authors/readers for more resources
Balamuthia mandrillaris is an under-reported, pathogenic free-living amoeba that causes Balamuthia amoebic encephalitis (BAE) and cutaneous skin infections. Although cutaneous infections are not typically lethal, BAE with or without cutaneous involvement is usually fatal. This is due to the lack of drugs that are both efficacious and can cross the blood-brain barrier. We aimed to discover new leads for drug discovery by screening the open-source Medicines for Malaria Venture (MMV) Malaria Box and MMV Pathogen Box, with 800 compounds total. From an initial single point screen at 1 and 10 mu M, we identified 54 hits that significantly inhibited the growth of B. mandrillaris in vitro. Hits were reconfirmed in quantitative dose-response assays and 23 compounds (42.6%) were confirmed with activity greater than miltefosine, the current standard of care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available